HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

496.758

-15.630-3.05%

Number of Gainers:6

Number of Losers:25

Number of Flat:2

PE:- -

High:512.373

Open:512.373

Low:495.812

Close:512.388

Volume:95.41M

Turnover:2.18B

Market Cap:315.16B

Float Cap:281.17B

Loading ...

Kintor Pharma Completes 52-Week Human Safety Trial of Skin-Whitening Ingredient KT-939

Sichuan Biokin Pharmaceutical to Engage Investors at Star Market Innovation Drug Sector Earnings Briefing

Hong Kong Stock Connect Biotech Surges: Dual-Antibody Outperforms Keytruda, Sector Heats Up

KeyMed Bio-B Announces Departure of Non-Executive Director

Keymed Biosciences Files Board, Committee Member List with Disclosure Roles

Keymed Biosciences Non-Executive Director Min Chuan Wang Resigns

Suzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators

Dizhe Pharma Stock Drops Over 5% After Insider Sell-Off Plan; Company Affirms Long-Term Confidence

Innovative Drug Indices Rally, ETFs See Inflows, CXO and Research Services Show Strong Momentum

Critical Safety Flaws in Huatai Pharmaceutical's Emergency Drug Lead to Exclusion from National Procurement Program

AI Integration Becomes Essential for Biopharma's Future, Says Henlius CEO

Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder

ALEBUND-B (09637) H Shares Set to Join Stock Connect and Hang Seng Composite Index

Traditional Chinese Medicine Firm Secures Regulatory Approval for New Depression Treatment

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

康宁杰瑞制药-B于9月4日斥资约49万港元回购5.6万股

Alphamab Oncology Files HKEX Next-Day Disclosure Return on Share Repurchase at HKD 8.79 Each

Zhaoke Ophthalmology Says Presbyopia Eye Drop Yuvezzi Meets Primary Endpoint in China Phase II Trial

China Galaxy Securities Forecasts High-Growth Prospects in Innovative Drug Sector Driven by Commercialization and Out-Licensing Deals

Assessing the Value of InnoCare's ICP-488 in the Psoriasis Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK1574/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":496.75812,"timestamp":1789027721934,"preClose":512.3882,"halted":0,"volume":95412163,"delay":0,"changeRate":-0.030504,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-15.630066,"latestTime":"09-10 16:00:00","open":512.3731,"high":512.3731,"low":495.81204,"amount":2180840440,"amplitude":0.032321,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"pbRate":3.809281,"peRate":169.439728,"turnoverRate":0.003564,"increases":5,"decrements":26,"flats":1,"marketCap":315159581920,"floatMarketCap":281174468760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":512.3731,"amplitude":0.032321,"preClose":512.3882,"low":495.81204,"pbRate":"3.809281","latestPrice":496.75812,"volume":95412163,"delay":0,"open":512.3731,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":515.473,"twentyDayClose":536.134,"sixtyDayClose":437.19,"secType":"PLATE","market":"HK","turnoverRate":0.003564,"peRate":169.439728,"marketCap":315159581920,"floatMarketCap":281174468760,"timestamp":1789027721934,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665438367","title":"Kintor Pharma Completes 52-Week Human Safety Trial of Skin-Whitening Ingredient KT-939","url":"https://stock-news.laohu8.com/highlight/detail?id=2665438367","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665438367?lang=en_us&edition=fundamental","pubTime":"2026-09-07 06:08","pubTimestamp":1788732492,"startTime":"0","endTime":"0","summary":"Kintor Pharma completes 52-week human safety trial of skin-whitening ingredient KT-939Kintor Pharmaceutical completed a 52-week long-term human safety trial of KT-939 on Sept. 4, 2026.Preliminary resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nNDL4qRNq1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167267027","title":"Sichuan Biokin Pharmaceutical to Engage Investors at Star Market Innovation Drug Sector Earnings Briefing","url":"https://stock-news.laohu8.com/highlight/detail?id=1167267027","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167267027?lang=en_us&edition=fundamental","pubTime":"2026-09-06 20:40","pubTimestamp":1788698452,"startTime":"0","endTime":"0","summary":"On September 6, Sichuan Biokin Pharmaceutical Co., Ltd. (688506) issued a notice confirming its participation in the Star Market’s collective earnings briefing for the innovation drug sector covering...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LNGR","MEDX","688506","BK0239","BK1161","06978","159992","KSTR","IBBQ","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129584734","title":"Hong Kong Stock Connect Biotech Surges: Dual-Antibody Outperforms Keytruda, Sector Heats Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1129584734","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129584734?lang=en_us&edition=fundamental","pubTime":"2026-09-06 19:22","pubTimestamp":1788693744,"startTime":"0","endTime":"0","summary":"The Hong Kong Stock Connect innovative drug sector finally sprung to life on September 4, posting its third consecutive session of gains with rising volume. The HUABAO HANG SENG HONG KONG STOCK...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0634319403.HKD","LU2778985437.USD","520880","LU2399975544.HKD","LU2476274308.USD","LU2488822045.USD","BK1574","LU0348766576.USD","LU0417516571.SGD","LU1720050803.USD","LU0348783233.USD","LU0348735423.USD","LU1961090484.USD","LU0348825331.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0561508036.HKD","BK1161","09926","LU0348784397.USD","LU0417516902.SGD","LU0348767384.USD","KURE","LU2476274720.SGD","LU0540923850.HKD","LU0348827113.USD","LU1794554557.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187916966","title":"KeyMed Bio-B Announces Departure of Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1187916966","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187916966?lang=en_us&edition=fundamental","pubTime":"2026-09-06 18:44","pubTimestamp":1788691467,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) has officially announced that Dr. Wang Minchuan has tendered his resignation as a non-executive director of the company.The resignation will take effect from September 4, 2026, as stated in the company's recent filing.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02162","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364508","title":"Keymed Biosciences Files Board, Committee Member List with Disclosure Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364508","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364508?lang=en_us&edition=fundamental","pubTime":"2026-09-06 18:32","pubTimestamp":1788690740,"startTime":"0","endTime":"0","summary":"Keymed Biosciences files board, committee member list with disclosure rolesKeymed Biosciences set its board lineup, dated Sept. 6, 2026, with three executive directors, two non-executive directors.Thr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nNDLcbVvQ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1574","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364549","title":"Keymed Biosciences Non-Executive Director Min Chuan Wang Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364549","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364549?lang=en_us&edition=fundamental","pubTime":"2026-09-06 18:29","pubTimestamp":1788690571,"startTime":"0","endTime":"0","summary":"Keymed Biosciences non-executive director Min Chuan Wang resignsKeymed Biosciences non-executive director Min Chuan Wang resigned effective Sept. 4, 2026.Departure cited other business commitments. No","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nNDLnQPNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1574","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108768389","title":"Suzhou Zelgen's New Thyroid Cancer Treatment Application Accepted by Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=1108768389","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108768389?lang=en_us&edition=fundamental","pubTime":"2026-09-06 15:38","pubTimestamp":1788680316,"startTime":"0","endTime":"0","summary":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SH) announced that it has recently received the official \"Acceptance Notification\" issued by China's National Medical Products Administration...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688266","IPOS","01477","BK0239","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129259024","title":"Dizhe Pharma Stock Drops Over 5% After Insider Sell-Off Plan; Company Affirms Long-Term Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1129259024","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129259024?lang=en_us&edition=fundamental","pubTime":"2026-09-06 15:11","pubTimestamp":1788678679,"startTime":"0","endTime":"0","summary":"Dizhe Pharma (also known as Dizhe Pharmaceutical) saw its share price tumble more than 5% on Thursday, September 4th, following a disclosure that four senior executives plan to reduce their holdings...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122138400","title":"Innovative Drug Indices Rally, ETFs See Inflows, CXO and Research Services Show Strong Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1122138400","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122138400?lang=en_us&edition=fundamental","pubTime":"2026-09-06 10:40","pubTimestamp":1788662438,"startTime":"0","endTime":"0","summary":"Over the past three months, three major innovative drug indices—the Shanghai Stock Exchange STAR Innovative Drug Index, the CSI Innovative Drug Industry Index, and the Hang Seng HK Stock Connect...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK4585","BK4550","MEDX","BK1574","WX","BK4588","CXO","BK1161","06978","FDN","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164754805","title":"Critical Safety Flaws in Huatai Pharmaceutical's Emergency Drug Lead to Exclusion from National Procurement Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1164754805","media":"Deep News","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164754805?lang=en_us&edition=fundamental","pubTime":"2026-09-05 15:20","pubTimestamp":1788592831,"startTime":"0","endTime":"0","summary":"A recent announcement from the National Medical Products Administration has revealed that a batch of amiodarone hydrochloride injection produced by Shandong Beida Hi-Tech Huatai Pharmaceutical failed...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158783895","title":"AI Integration Becomes Essential for Biopharma's Future, Says Henlius CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1158783895","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158783895?lang=en_us&edition=fundamental","pubTime":"2026-09-05 14:20","pubTimestamp":1788589217,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Summer Annual Meeting, held from September 4-6 in Chengdu, Sichuan, Zhu Jun, CEO of HENLIUS, stated that the primary mission of the healthcare industry is to help people live...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320223.HKD","01477","CHAT","BBP","HK0000306685.HKD","03069","MRNX","AIPO","HK0000165453.HKD","ARTY","BK1161","HK0000320264.USD","AGIX","BK1191","MRNY","BK1574","QTOC","VTHR","02696","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121796426","title":"Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796426","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796426?lang=en_us&edition=fundamental","pubTime":"2026-09-05 14:10","pubTimestamp":1788588618,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Summer Annual Meeting, held September 4-6 in Chengdu, Sichuan, under the theme \"Enterprise Innovation and Cycle Crossing,\" Formatia Founder and CEO Peng Lei offered a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","RSPH","PTH","LNGR","IBRN","09996","MDEV","LGHT","BK1100","HART","GDOC","BK1583","159883","BK1574","MNTL","IEIH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144923293","title":"ALEBUND-B (09637) H Shares Set to Join Stock Connect and Hang Seng Composite Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1144923293","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144923293?lang=en_us&edition=fundamental","pubTime":"2026-09-04 21:36","pubTimestamp":1788528973,"startTime":"0","endTime":"0","summary":"The Board of ALEBUND-B (09637) has announced that its H shares have been included in the list of eligible securities under the Stock Connect programme. This inclusion will take effect from Monday,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","HSCI","FLHK","BK1161","09637","BK1191","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103371342","title":"Traditional Chinese Medicine Firm Secures Regulatory Approval for New Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1103371342","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103371342?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:54","pubTimestamp":1788526459,"startTime":"0","endTime":"0","summary":"TRAD CHI MED (00570) has announced that its subsidiary, Guizhou Tongjitang Pharmaceutical Co., Ltd., has received official market authorization from the National Medical Products Administration...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK1574","IPOS","MEDX","LNGR","159992","BK1161","06978","BK1191","00570","BK1515","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188865864","title":"Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1188865864","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188865864?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:16","pubTimestamp":1788524178,"startTime":"0","endTime":"0","summary":"Hong Kong stocks ended the session firmly in positive territory, closing up 1.74% after a strong open, though momentum faded slightly into the close. The overnight surge on Wall Street, where all...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OEF","DPST","UDN","SPYI","NGHT","LU2399975544.HKD","BK4550","UBT","ISHG","VEXC","BK4588","DMAX","VCIT","BK4534","LU0348825331.USD","BK1161","BK1109","TNmain","HYGU","BWZ","BBLB","SMAX","SPXU","VOO","FAZ","LU0417516902.SGD","PBDC","BK1207","LQD","LQDU","VCSH","OOQB","09678","IE00BPRC5H50.USD","TLTW","IGOV","LU0417516738.SGD","VXUS","MESmain","MUNX","EBUF","IE00B543WZ88.USD","09926","LU1720050803.USD","WAMA","02714","GOLY","LU0348766576.USD","NEMD","SSO","UBmain","LU0348735423.USD","SHV","02698","AGG","SKRE","DBND","LU0540923850.HKD","BK4559","TLTX","SPYH","KBWB","SPXS","TBIL","LU0348767384.USD","TLH","BK1237","BOXX","VFH","SPYB","MUB","FLGV","KCAI","TYO","LU1961090484.USD","LU2476274308.USD","VGIT","HMOP","GOVT","HK0000165453.HKD","JPST","TSYW","USHY","HYG","SPYQ","HIBL","LU0417516571.SGD","LU0634319403.HKD","BBSB","BK4581","SH","MMAX","KURE","BND","TLT","XLF","EDV","LU2476274720.SGD","MYCN","TMF","VGSH","ZFmain","SPXL","HYGD","LU0348783233.USD","BK4535","IAT","BK4561","TIP","LU2778985437.USD","LU0348827113.USD","TBJL","KBE","SHY","MINT","VGLT","SGOV","SDS","BOND","TBT","IEI","LU0561508036.HKD","ESmain","SPUU","KRE","LIAJ","KRX","TFJL","ZBmain","LU1794554557.SGD","BK4585","BK4504","LQDD","LU2488822045.USD","BK1574","SPYU","JULD","BK1160","ZTmain","SPDN","YSPY","02419",".SPX","FEM","TLTI","IEF","OEX","IE00B5MMRT66.SGD","SPY","NELS","IVV","BSV","GBIL","BBIB","BWX","LU0348784397.USD","ZROZ","SPYM","EMPB","XBIL","UUP","SCHO","RAUS","XLRI","CIVG","BIL","UPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118036040","title":"康宁杰瑞制药-B于9月4日斥资约49万港元回购5.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118036040","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118036040?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:00","pubTimestamp":1788523218,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（09966）于2026年9月4日发布公告，披露其当日回购动作。公告显示，该公司在当天耗资49.243万港元，回购了5.6万股股份。此次回购行动体现了公司对自身价值的信心，并可能对市场情绪产生一定积极影响。","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339000","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return on Share Repurchase at HKD 8.79 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339000","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339000?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:54","pubTimestamp":1788522890,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return on share repurchase at HKD 8.79 eachAlphamab Oncology repurchased 56,000 ordinary shares on Sept. 4 for treasury, per HKEX next-day disclosure r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL2JKKnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336546","title":"Zhaoke Ophthalmology Says Presbyopia Eye Drop Yuvezzi Meets Primary Endpoint in China Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336546","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664336546?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:39","pubTimestamp":1788518398,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology says presbyopia eye drop YUVEZZI meets primary endpoint in China Phase II trialZhaoke Ophthalmology reported its YUVEZZI presbyopia eye drop met the primary endpoint in a China Ph","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5kNMcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","06622","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125606398","title":"China Galaxy Securities Forecasts High-Growth Prospects in Innovative Drug Sector Driven by Commercialization and Out-Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=1125606398","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125606398?lang=en_us&edition=fundamental","pubTime":"2026-09-04 16:42","pubTimestamp":1788511349,"startTime":"0","endTime":"0","summary":" China Galaxy Securities has released a research report indicating that after a significant pullback in the pharmaceutical sector during the first half of the year, valuations for both innovative and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","06881","BK1147","159992","MEDX","BK1161","601881","IBBQ","BK0188","BK1564","BK1574","LNGR","BK0276","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143374133","title":"Assessing the Value of InnoCare's ICP-488 in the Psoriasis Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1143374133","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143374133?lang=en_us&edition=fundamental","pubTime":"2026-09-04 15:30","pubTimestamp":1788507030,"startTime":"0","endTime":"0","summary":"For innovative drug companies, valuation hinges on pipeline potential, and InnoCare's lead asset in the autoimmune space, the highly selective TYK2 allosteric inhibitor ICP-488 (Fadeucravacitinib),...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","688428","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":5,"totalSize":255,"code":"91000000","status":"200"}]}}